Development of an active wound dressing built with electrospun jellyfish collagen and capable of delivering natural antimicrobial agents
Lead Participant:
NEEM BIOTECH LTD
Abstract
Biofilms are present in chronic wounds and are known to contribute to continued infection and inflammation
with antibiotic resistance of biofilms complicating the problem. Current wound healing treatments are
associated with antibiotic resistance and often use mammalian (bovine) collagen treatments, which risks
contamination from disease causing agents such as prions (Bovine spongiform encephalopathy) and
interspecies viruses. In the present Feasibility Study, by embedding jellyfish collagen with novel plant derived
antimicrobials, it will be possible to produce a prototype product capable of delivering antimicrobial agents
directly to the wound and reduce the need for antibiotics.
By combating biofilms in chronic wounds, the consortium will reduce the burden on the NHS and drastically
improve the quality of life of chronic wound sufferers. The wound healing product output of this project will
address the current problems with wound chronicity that contribute to this growing problem in the UK.
with antibiotic resistance of biofilms complicating the problem. Current wound healing treatments are
associated with antibiotic resistance and often use mammalian (bovine) collagen treatments, which risks
contamination from disease causing agents such as prions (Bovine spongiform encephalopathy) and
interspecies viruses. In the present Feasibility Study, by embedding jellyfish collagen with novel plant derived
antimicrobials, it will be possible to produce a prototype product capable of delivering antimicrobial agents
directly to the wound and reduce the need for antibiotics.
By combating biofilms in chronic wounds, the consortium will reduce the burden on the NHS and drastically
improve the quality of life of chronic wound sufferers. The wound healing product output of this project will
address the current problems with wound chronicity that contribute to this growing problem in the UK.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
NEEM BIOTECH LTD | £31,271 | £ 21,890 |
  | ||
Participant |
||
JELLAGEN PTY LTD | £33,103 | £ 23,172 |
MEMBRANOLOGY LIMITED | £33,948 | £ 23,763 |
People |
ORCID iD |